Genetic and protein expression analyses of patient tissue samples demonstrated that c-Met activation is closely associated with tumor progression and metastasis in breast and prostate cancers, with a higher expression in the metastatic lesions compared to the primary lesions [22,23,24,25]. This evidence concerns the gene MET and prostate carcinoma.